SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Top Headlines

Exclusive interview

Preclinical prices improving says Huntingdon CEO; firm is mulling US capacity expansion

Higher capacity utilization is improving prices across the non-clinical research sector according to Huntingdon Life Sciences CEO Brian Cass, who told Outsourcing-pharma.com the preclinical CRO may add scale to US operations.

CRL’s bottom line continues to be driven by biotech growth, CEO says

For the second straight year Charles River Laboratories has seen more of its revenue derived from biotech companies than Big Pharma, CEO James Foster told investors at two conferences on Tuesday and Wednesday.

Patheon: Irix deal about US and Canadian customer demand for local APIs; all staff to be retained

Irix Pharmaceuticals will cater for North American customers’ desire for local supply according to Patheon, which says it plans to retain the API firm’s 180 staff.

PEOPLE ON THE MOVE

On the move in outsourcing

Our who's who of the latest appointments at CROs, CMOs, services companies and pharmaceutical communications.

Rho offers support for NIH trial on peanut allergies

CRO (Contract Research Organization) Rho collaborated with the NIH (National Institutes of Health) on its most recent study that found a major reduction of peanut allergies in children who began early, continuous consumption of peanuts.

Cromos launches cardiology-based site research organization in Russia

Moscow-based Cromos Pharma, an international full-service CRO, has launched Cardiorus, a cardiology and cardiothoracic surgery site research organization (SRO), with its clinical base being at the Bakoulev Center of Cardiovascular Surgery in Moscow.

Valeant sacks Dendreon admin staff and plans manufacturing savings

Valeant has started cutting jobs at Provenge manufacturer Dendreon just over a week after it acquired the bankrupt firm for $495m.

Spotlight

Researchers enthusiastic over Obama’s new $215m precision medicine initiative

Researchers enthusiastic over Obama’s new $215m precision medicine initiative

In what was largely a pep rally for science, President Obama on Friday unveiled his $215m precision...

Parexel sees book-to-bill bounce back as GSK strategic partnership renewal bears fruit

Parexel sees book-to-bill bounce back as GSK strategic partnership renewal bears fruit

One quarter after announcing a disappointing book-to-bill ratio, CRO Parexel has now renewed its strategic partnership with...

AstraZeneca turns to CRISPR for drug discovery; Are you watching Cellectis?

AstraZeneca turns to CRISPR for drug discovery; Are you watching Cellectis?

AstraZeneca has partnered to use the CRISPR genome editing technique across its discovery programmes in a move...

HCV drugs Sovaldi and Olysio boost Q1 sales for AmeriSourceBergen

HCV drugs Sovaldi and Olysio boost Q1 sales for AmeriSourceBergen

New hepatitis C drugs produced by Gilead, Janssen and AbbVie contributed to a first quarter spike in...

Strong USD to hit revenues but strategic CROs may see lower costs

Strong US Dollar to hit revenues but strategic CROs may see lower costs

The strengthening US Dollar will reduce CRO revenues, say analysts, but firms which have global strategic deals...

Biosimulation – the next step in PK modelling embraced by regulators

Biosimulation – the next step in PK modelling embraced by regulators

Computer-based drug modelling is moving from a discovery aid to a clinical tool accepted by regulators, according...